Rennova Health, Inc. (NASDAQ:RNVA) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02.
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On May 24, 2017, the Board of Directors of Rennova Health, Inc.
(the Company) appointed Michael Pollack as its interim Chief
Financial Officer.
Michael Pollack, 51, has been a partner of KBL LLP, a certified
public accounting and business advisory services firm, since 2005
and has approximately 30 years of experience in public accounting
and consulting to over 100 publicly traded and 250 private
companies.Mr. Pollack graduated from the University of Maryland
with a Bachelors of Arts in Economics. Mr. Pollack is a member of
the American Institute of Certified Public Accountants, as well
as licensed to practice in New Jersey, Pennsylvania, New York and
Maryland.
Mr. Pollack has no family relationship with any of the executive
officers or directors of the Company. There are no arrangements
or understandings between Mr. Pollack and any other person to
which he was appointed as an officer of the Company.
A copy of the press release issued by the Company announcing Mr.
Pollacks appointment is attached hereto as Exhibit 99.1 and is
incorporated by reference herein.
| Item 9.01. | Financial Statements and Exhibits. |
(d)Exhibits
| Exhibit No. | Exhibit Description |
| 99.1 | Press Release dated May 25, 2017 |
About Rennova Health, Inc. (NASDAQ:RNVA)
Rennova Health, Inc. (Rennova), formerly CollabRx, Inc., is a provider of diagnostics and supportive software solutions to healthcare providers. The Company operates in three segments: clinical laboratory operations, supportive software solutions, and decision support and informatics operations. The Company is a healthcare enterprise that delivers products and services, including laboratory diagnostics, healthcare technology solutions, and revenue cycle management and intends to provide financial services, to medical providers. Rennova’s principal line of business is clinical laboratory blood and urine testing services. It is also engaged in the provision of urine drug toxicology testing to physicians, clinics and rehabilitation facilities in the United States. Its clinical laboratories include Biohealth Medical Laboratory, Inc.; Alethea Laboratories, Inc.; International Technologies, LLC; EPIC Reference Labs, Inc., and Epinex Diagnostics Laboratories, Inc. Rennova Health, Inc. (NASDAQ:RNVA) Recent Trading Information
Rennova Health, Inc. (NASDAQ:RNVA) closed its last trading session up +0.039 at 0.429 with 582,202 shares trading hands.